Condition: Phenylketonuria · Sponsor: PTC Therapeutics
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The main purpose of this study is to evaluate the long-term safety of PTC923 in participants with phenylketonuria, and to evaluate the changes from baseline in dietary phenylalanine (Phe)/protein consumption.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Children's Hospital Colorado | Aurora, Colorado, United States | — |
| UF College of Medicine, Department of Pediatrics Division of Genetics and Metabolism | Gainesville, Florida, United States | — |
| Indiana University School of Medicine Department of Medical and Molecular Genetics | Indianapolis, Indiana, United States | — |
| Boston Children's Hospital | Boston, Massachusetts, United States | — |
| Icahn School of Medicine at Mount Sinai (ISMMS) | New York, New York, United States | — |
| UPMC Children's Hospital of Pittsburgh | Pittsburgh, Pennsylvania, United States | — |
| University of Utah | Salt Lake City, Utah, United States | — |
| The Queensland Children's Hospital | South Brisbane, Brisbane, Australia | — |
| Westmead Hospital | Westmead, New South Wales, Australia | — |
| PARC Clinical Research | Adelaide, South Australia, Australia | — |
| Royal Children's Hospital | Parkville, Victoria, Australia | — |
| Hospital de clinicas de Porto Alegre | Porto Alegre, Rio Grande do Sul, Brazil | — |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.